Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

被引：24
|
作者：
Montemorano, Lauren [1 ]
Lightfoot, Michelle D. S. [2 ]
Bixel, Kristin [2 ]
机构：
[1] Ohio State Univ, Dept Obstet & Gynecol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, James Canc Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Columbus, OH 43210 USA
来源：
ONCOTARGETS AND THERAPY | 2019年 / 12卷
关键词：
olaparib; PARP inhibitor; ovarian cancer; maintenance; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; BEVACIZUMAB; INHIBITORS; CARCINOMA;
D O I：
10.2147/OTT.S195552
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
引用
收藏
页码：11497 / 11506
页数：10
相关论文
共 50 条
  • [31] Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer EDITORIAL COMMENT
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2019, 74 (02) : 86 - 87
  • [32] Olaparib for the treatment of BRCA-mutated advanced ovarian cancer
    Munroe, Marklie
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (14) : 1037 - 1041
  • [33] The Role of Maintenance Therapy in Ovarian Cancer
    Oza, Amit M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 98 - 101
  • [34] Olaparib in the management of ovarian cancer
    Bixel, Kristin
    Hays, John L.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 127 - 135
  • [35] Frontline Maintenance Treatment for Ovarian Cancer
    Elyashiv, Osnat
    Wong, Yien Ning Sophia
    Ledermann, Jonathan A.
    CURRENT ONCOLOGY REPORTS, 2021, 23 (08)
  • [36] Frontline Maintenance Treatment for Ovarian Cancer
    Osnat Elyashiv
    Yien Ning Sophia Wong
    Jonathan A. Ledermann
    Current Oncology Reports, 2021, 23
  • [37] A Retrospective Analysis of Clinical Biomarkers for Olaparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer
    Endo, Shun
    Shigeta, Shogo
    Tokunaga, Hideki
    Shimizu, Takanori
    Hasegawa-Minato, Junko
    Hashimoto, Chiaki
    Ishibashi, Masumi
    Nagai, Tomoyuki
    Shiga, Naomi
    Shimada, Muneaki
    Yaegashi, Nobuo
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 258 (01): : 1 - 9
  • [38] Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan
    Hsu, Chia-Chen
    Pan, Yu-Bin
    Lai, Chyong-Huey
    Chang, Ting-Chang
    Yang, Lan-Yan
    Chou, Hung-Hsueh
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2021, 60 (04): : 634 - 638
  • [39] Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
    Rojas-Roque, Carlos
    Silvestrini, Constanza
    Argento, Fernando
    Sugg, Daniela
    Augustovski, Federico
    Coelli, Jesica
    Espinola, Natalia
    PHARMACOECONOMICS-OPEN, 2024, 8 (04) : 585 - 598
  • [40] MAINTENANCE OLAPARIB IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A COMPREHENSIVE CANCER CENTRE'S EXPERIENCE
    Moreira, I.
    Ferreira, M.
    Lopes, A. R.
    Savva-Bordalo, J.
    Abreu, M.
    Sousa, S.
    Pereira, D.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A241 - A241
12345